Journal of Clinical and Translational Endocrinology最新文献

{"title":"PCSK7 levels in women with and without PCOS","authors":"Stephen L. Atkin , Alexandra E Butler , Tannaz Jamialahmadi , Amirhossein Sahebkar","doi":"10.1016/j.jcte.2024.100376","DOIUrl":"10.1016/j.jcte.2024.100376","url":null,"abstract":"","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100376"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The right drug for the right patient at the right time with the right test in differentiated thyroid cancer (DTC)","authors":"Dario de Biase ,&nbsp;Andrea Repaci ,&nbsp;Maria Concetta Nigro ,&nbsp;Thais Maloberti ,&nbsp;Francesca Carosi ,&nbsp;Maria A. Pantaleo ,&nbsp;Giovanni Tallini ,&nbsp;Margherita Nannini","doi":"10.1016/j.jcte.2024.100373","DOIUrl":"10.1016/j.jcte.2024.100373","url":null,"abstract":"<div><div>Thanks to the identification of crucial molecular pathways, the therapeutic landscape for advanced differentiated thyroid tumors (DTCs) has significantly improved during the last ten years. The therapeutic scenario has been greatly impacted by the discovery of mutually exclusive gene changes in the MAPK and PI3K/AKT pathways, such as <em>RET</em> or <em>NTRK</em> fusions and pathogenic mutations of the <em>BRAF</em> and <em>RAS</em> genes. Indeed, multi-kinase inhibitors and selective inhibitors have demonstrated outstanding efficacy for radioactive iodine-refractory (RAI-R) drug treatment, with overall response rates reaching up to 86%. Thus, for RAI-R DTCs, routine molecular testing for actionable gene alterations is now essential, for choosing the right therapy for the right patient.</div><div>Additionally, tumor genotyping also allows to identify a subset of patients with worse prognosis disease, which may deserve a tailored clinical management. Thus, the right test should also include non-driver <em>TERT</em>, <em>TP53</em>, <em>PIK3CA</em>, and other mutations of aggressiveness, with the aim of a molecular-based risk stratification. Therefore, tumor genotyping should be considered in the diagnostic work-up of metastatic DTC patients or with highly aggressive histological features, in order to give the right drug for the right patient at the right time.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100373"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143161734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eating habits and carotenoid skin content among children based on their attendance at the school meals: A cross-sectional pilot study","authors":"Giovanna Caparello ,&nbsp;Fabrizio Ceraudo ,&nbsp;Francesca Meringolo ,&nbsp;Giuseppina Augimeri ,&nbsp;Giuseppe Morino ,&nbsp;Daniela Bonofiglio","doi":"10.1016/j.jcte.2024.100378","DOIUrl":"10.1016/j.jcte.2024.100378","url":null,"abstract":"<div><h3>Objective</h3><div>The promotion of a healthy diet, such as the Mediterranean Diet (MD), among childhood is of a particular importance, since eating behaviors learned early in life have been shown to be maintained into adolescence and adulthood. The most efficient intervention in childhood is the active involvement of the schools.</div></div><div><h3>Design</h3><div>The aim of this study was to evaluate the adherence to the MD model and the skin carotenoid levels among children divided by their school lunch attendance.</div></div><div><h3>Methods</h3><div>This cross-sectional study involved 132 pupils (64 girls and 68 boys), divided between children who ate lunch at school (44%) and at home (56%). The children who had meals provided by the school participated in activities promoting the health benefits of fruits and vegetables. All participants underwent anthropometric measurements and assessment of the MD adherence and the physical activity using KIDMED and PAQ-C questionnaires, respectively, and skin carotenoid content using the Veggie Meter®.</div></div><div><h3>Results</h3><div>We found mean KIDMED and PAQ-C scores, while skin carotenoid content was below the normal range in our population sample. Interestingly, children who ate lunch provided by the school had significantly higher carotenoid scores with respect to those who had lunch at home (<em>p = 0.005</em>). In multiple regression analyses, we found that carotenoid scores were positively influenced by gender (<em>p = 0.03</em>), school lunch attendance (<em>p = 0.01</em>) and daily vegetable consumption (<em>p = 0.0002</em>) in our children population sample.</div></div><div><h3>Conclusions</h3><div>Our results suggest the importance of promoting a healthy lifestyle at the school to improve eating habits during childhood as a strategy for disease prevention across the lifespan.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100378"},"PeriodicalIF":4.2,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of diabetes in correctional facilities: A global systematic review and meta-analysis","authors":"Muhammed Shabil ,&nbsp;Shilpa Gaidhane ,&nbsp;Sorabh Lakhanpal ,&nbsp;Sara Irshaidat ,&nbsp;Suhas Ballal ,&nbsp;Sanjay Kumar ,&nbsp;Mahakshit Bhat ,&nbsp;Shilpa Sharma ,&nbsp;M. Ravi Kumar ,&nbsp;Sarvesh Rustagi ,&nbsp;Mahalaqua Nazli Khatib ,&nbsp;Sunil Kumar Mishra ,&nbsp;Sanjit Sah ,&nbsp;Hashem Abu Serhan ,&nbsp;Ganesh Bushi ,&nbsp;Bijaya K. Padhi","doi":"10.1016/j.jcte.2024.100374","DOIUrl":"10.1016/j.jcte.2024.100374","url":null,"abstract":"<div><h3>Background</h3><div>Diabetes mellitus presents significant public health challenges worldwide. While its prevalence and management in the general population have been extensively studied, comprehensive research on diabetes among incarcerated individuals is lacking. This study aims to conduct a systematic review and <em>meta</em>-analysis to determine the prevalence of diabetes within the prison population.</div></div><div><h3>Methods</h3><div>The systematic review included studies reporting on the prevalence of diabetes in prison populations. Searches were conducted in PubMed, Web of Science, and EMBASE from 2000 to November 4, 2023, with an update on December 15, 2023. Nested Knowledge web software was utilized for screening and data extraction. Quality assessment was conducted using the JBI tool. A <em>meta</em>-analysis was performed using a random-effects model in R software version 4.3.</div></div><div><h3>Results</h3><div>Thirty-three studies were included, encompassing 807,617 participants, with 67,291 reported as patients with diabetes. The pooled prevalence of diabetes in prison populations was found to be 7.1% (95% CI: 4.9% to 10.1%), exhibiting high heterogeneity (I² = 100%). Subgroup analysis revealed significant geographical variability: the United States had a prevalence of 9% (95% CI: 4 %to 17 %), Italy 5% (95% CI: 0% to 40 %), Iran 10% (95% CI: 7 % to 15 %), and Egypt 21% (95% CI: 14% to 28 %). Notable variations in prevalence were also observed in countries like France, Australia, Taiwan, India, the UK, Spain, Brazil, and Sub-Saharan Africa. An LFK index of −3.3 indicated the presence of publication bias.</div></div><div><h3>Conclusion</h3><div>The study reveals that diabetes mellitus is a significant health concern in prisons, with a prevalence of 7.1%, comparable to that in the general population. The marked variability across studies indicates the challenges of diabetes management in correctional settings. These findings highlight the need for tailored healthcare strategies, considering prisons’ unique challenges and risk factors.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"39 ","pages":"Article 100374"},"PeriodicalIF":4.2,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11719280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review","authors":"Ammar Ahmed ,&nbsp;Anvitha Ankireddypalli ,&nbsp;Tasma Harindhanavudhi ,&nbsp;Antoinette Moran ,&nbsp;Amir Moheet","doi":"10.1016/j.jcte.2024.100375","DOIUrl":"10.1016/j.jcte.2024.100375","url":null,"abstract":"<div><div>Cystic fibrosis-related diabetes (CFRD) is the most common non-pulmonary comorbidity in people with cystic fibrosis (CF). Current guidelines recommend insulin therapy as the treatment of choice for people with CFRD. In the past, obesity and overweight were uncommon in individuals with CF. However, in recent years, advancements in CF therapies have led to a significant increase in the prevalence of overweight and obesity within this population. Glucagon-like peptide1 receptor agonist (GLP-1 RA) therapies could potentially improve glycemic control in people with CF by increasing insulin secretion, slowing gastric emptying, and promoting weight loss through central appetite suppression, which in turn can enhance insulin sensitivity. We report, for the first time, five cases of individuals with CFRD complicated by obesity treated with GLP 1-RA for at least two years. With GLP 1-RA therapy, 4 out of 5 individuals exhibited weight reduction ranging from 7% to 19% over two years, while forced expiratory volume in 1 s (FEV1)/predicted FEV1 % remained stable or improved in all cases. The impact on glycemic control was variable. Insulin requirements either reduced or remained stable in all five cases. Overall, GLP-1 RA was well tolerated in this case series; one individual discontinued the medication after two years of therapy due to poor appetite and nausea.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100375"},"PeriodicalIF":4.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142655723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands","authors":"Dide de Jongh ,&nbsp;Eline Bunnik ,&nbsp;Behiye Ozcan ,&nbsp;Robert Zietse ,&nbsp;Emma Massey ,&nbsp;VANGUARD consortium","doi":"10.1016/j.jcte.2024.100372","DOIUrl":"10.1016/j.jcte.2024.100372","url":null,"abstract":"<div><h3>Aims</h3><div>Healthcare professionals are relevant stakeholders because of their gatekeeper role in the clinic. This study aims to explore their perspectives on the potential future clinical implementation of the bio-artificial pancreas (BAP) for people with type 1 diabetes, and suitable target groups.</div></div><div><h3>Methods</h3><div>Semi-structured interviews were conducted with 17 healthcare professionals, including endocrinologists, nurses, and pancreas transplant surgeons. Inclusion was stopped once data saturation was reached. The audiotaped interviews were transcribed verbatim. Qualitative content analysis using an inductive approach was conducted to develop themes within a coding framework.</div></div><div><h3>Results</h3><div>Three main themes emerged: (1) hoped-for benefits, which included improved clinical outcomes, enhanced sense of normality, reduced mental burden for patients and their significant others, greater societal participation, and lower costs; (2) concerns, which included safety and effectiveness, inequitable access, accurate information, control over self-management, and organizational challenges; and (3) allocating the BAP during initial implementation, which included prioritizing people who lack effective treatment options, people with mental health issues, and vulnerable people.</div></div><div><h3>Conclusions</h3><div>The results of this study are important for researchers and practitioners involved in the development of the BAP, so that they can align its design and the process of clinical implementation with healthcare professionals’ perspectives.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100372"},"PeriodicalIF":4.2,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142527368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics of Ketosis Prone Diabetes: Evaluating diagnosis and management practices in a real-life setting","authors":"Zunera Tariq ,&nbsp;Anusha Sinha ,&nbsp;Gina Shokry ,&nbsp;Kelly Moors ,&nbsp;Sai Sripad Kodukula ,&nbsp;Carmella Evans-Molina ,&nbsp;Zeb Ijaz Saeed","doi":"10.1016/j.jcte.2024.100371","DOIUrl":"10.1016/j.jcte.2024.100371","url":null,"abstract":"","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100371"},"PeriodicalIF":4.2,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142426065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study","authors":"Arunkumar Krishnan ,&nbsp;Carolin V. Schneider ,&nbsp;Hendrik-Tobias Arkenau ,&nbsp;Ezequiel Matias Mauro ,&nbsp;Alejandro Forner ,&nbsp;W. Scott Butsch ,&nbsp;Declan Walsh ,&nbsp;Saleh A. Alqahtani","doi":"10.1016/j.jcte.2024.100370","DOIUrl":"10.1016/j.jcte.2024.100370","url":null,"abstract":"<div><h3>Aim</h3><div>To examine the association between the use of incretin-based drugs [glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4Is)] and the risk of cholangiocarcinoma (CCA) in the United States.</div></div><div><h3>Methods</h3><div>This large population-based, retrospective cohort study using the TriNetX datasets included adult patients with type 2 diabetes mellitus (T2DM) who were new users of GLP-1RAs, DPP-4Is, or other second- or third-line antidiabetic drugs between 2010 and 2021. The primary outcome was the incidence of CCA.</div></div><div><h3>Results</h3><div>A total of 3,816,071 patients were included (mean age, 61.4 years, female, 49.3 %). A 51 % and 23 % risk reduction in CCA after 1 year of exposure to GLP-1RAs (hazard ratio 0.49; 95 % CI 0.40–0.60) and DPP4Is (0.77, 95 % CI 0.67–0.90), respectively compared to new second-or third-line users. Results were consistent at 3, 5, and 7 years of follow-up (0.66, 0.71, and 0.72 for GLP-1RAs and 0.84, 0.87, and 0.85 for DPP-4Is, respectively). Compared to new metformin users, GLP-1RA users were associated with a 42 % lower risk of developing CCA, whereas DPP-4I group was not associated with an increased risk.</div></div><div><h3>Conclusions</h3><div>GLP-1RAs and DPP-4Is were not associated with a significantly increased risk of CCA. GLP-1RAs even showed a reduced risk of CCA development. They can be considered as safe and effective treatment options for patients with T2DM at risk of CCA.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100370"},"PeriodicalIF":4.2,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142320285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation study of multiple inflammatory indices and vertebral compression fracture: A cross-sectional study","authors":"Qi Fu,&nbsp;Cuiping Zhang,&nbsp;Yujiao Yang,&nbsp;Ruoling Teng,&nbsp;Fenfen Liu,&nbsp;Ping Liu,&nbsp;Long Wang,&nbsp;Jiao Wang,&nbsp;Yanan Chen,&nbsp;Yi Ding","doi":"10.1016/j.jcte.2024.100369","DOIUrl":"10.1016/j.jcte.2024.100369","url":null,"abstract":"<div><h3>Background</h3><p>Vertebral compression fractures (VCFs) are prevalent in patients with osteoporosis and pose significant health risks. Although chronic low-grade inflammation plays a crucial role in the pathogenesis of osteoporosis, the relationship between various inflammatory indices and the occurrence of fractures remains unclear.</p></div><div><h3>Objective</h3><p>This study aims to evaluate the correlation between multiple inflammatory indices, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammatory index (SII), and systemic inflammatory response index (SIRI), and VCFs, to explore the significance of these indices in clinical application.</p></div><div><h3>Methods</h3><p>Clinical data of 310 patients diagnosed with osteoporosis from November 2020 to June 2023 in the hospital were collected. The general conditions between fracture and non-fracture groups were described. Spearman analysis and binary logistic regression analysis were used to assess the relationship between inflammatory indices and VCFs. Receiver operating characteristic curve was used to evaluate the diagnostic efficacy of these inflammatory indices for VCFs.</p></div><div><h3>Results</h3><p>VCFs were diagnosed in 43.55 % of patients with osteoporosis. NLR(ρ = 0.169, P=0.003), MLR(ρ = 0.293, P&lt;0.001), SII(ρ = 0.126, P=0.027), and SIRI(ρ = 0.273, P&lt;0.001) were positively correlated with the occurrence of VCFs. NLR(OR=1.480, 95 %CI 1.114 ∼ 1.966, P=0.007), MLR(multiplied by 100, OR=1.048, 95 %CI 1.011 ∼ 1.087, P=0.011), and SIRI(OR=3.327, 95 %CI 1.510 ∼ 7.330, P=0.003) were independent risk factors for VCFs, hip bone mineral density (BMD) (OR=0.011, 95 %CI 0.001 ∼ 0.151, P=0.001) was an independent protective factor for VCFs. MLR(AUC 0.671, 95 % CI=0.610 ∼ 0.732, P &lt;0.001) had relatively high clinical diagnostic efficacy.</p></div><div><h3>Conclusion</h3><p>The neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and systemic inflammatory response index (SIRI) are independent risk factors for vertebral compression fractures.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"37 ","pages":"Article 100369"},"PeriodicalIF":4.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000401/pdfft?md5=086e3465529475372986cf9dfc5feee5&pid=1-s2.0-S2214623724000401-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142164396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperandrogenic eumenorrheic NON-PCOS women versus women with PCOS after the GnRH-agonist stimulation test preceded by suppression of adrenal steroidogenesis with dexamethasone","authors":"Salvatore Benvenga ,&nbsp;Michele Russo ,&nbsp;Gianpiero Forte ,&nbsp;Vittorio Unfer","doi":"10.1016/j.jcte.2024.100368","DOIUrl":"10.1016/j.jcte.2024.100368","url":null,"abstract":"&lt;div&gt;&lt;p&gt;The subject of polycystic ovary syndrome (PCOS) has been extensively covered in the literature; however, there is a paucity of data regarding eumenorrheic women with hyperandrogenism and/or hyperandrogenemia without ultrasound evidence of PCO morphology (EuHyperA), and even less data on the comparison between PCOS and EuHyperA subjects. It has previously been shown that around half of PCOS women exhibit a hyper-response of serum 17-hydroxy-progesterone (17-OHP) to the stimulation by GnRH-agonists, also indicated as functional ovarian hyperandrogenism (FOH). Often, this stimulation test is preceded by suppression of the adrenal steroidogenesis with oral dexamethasone (Dex). FOH has been associated with an increase of the P450c17 activity in the ovaries driven by elevated insulin levels. Interestingly, treatment of women with PCOS with Dex suppression and GnRH-agonist stimulation (buserelin) highlighted the possible existence of two clusters of patients: hyper-responders (HR) and normal responders (NR).&lt;/p&gt;&lt;p&gt;In this retrospective study, we included 15 hyper-responders (HR) EuHyperA, 34 normal responders (NR) EuHyperA, 62 HR-PCOS and 45 NR-PCOS. The demographic characteristics, glucose-metabolism indices, and the hormonal response to Dex or buserelin were analyzed, with both intra-group and inter-group comparisons performed.&lt;/p&gt;&lt;p&gt;The rate of FOH was significantly greater in PCOS than EuHyperA women. Compared to HR-PCOS, HR-EuHyperA had [i.] significantly greater age at observation; [ii.] lower cortisol, 17-OHP, Δ4-androstenedione (Δ4-ASD), total testosterone (TT), LH, and buserelin-stimulated whole curve of dehydroepiandrosterone sulfate (DHEAS), 17-OHP, Δ4-ASD and TT. Compared to NR-PCOS, NR-EuHyperA had [i.] significantly greater FSH, and buserelin-stimulated whole curve of DHEAS; [ii.] significantly lower post-HD Dex Δ4-ASD, TT, buserelin-stimulated whole curve of 17-OHP, Δ4-ASD and TT. Compared to NR-PCOS, HR-PCOS had [i.] significantly greater body mass index (BMI), homeostasis model assessment for insulin resistance (HOMA-IR), cortisol, DHEAS, Δ4-ASD, TT, FT, FAI, E2, and insulin AUC&lt;sub&gt;0-120min&lt;/sub&gt; (area under the curve) at oral glucose tolerance test (OGTT); [ii] higher levels of post-LD and post-HD Dex 17-OHP, Δ4-ASD, TT, post-HD Dex DHEAS (with greater levels indicating weaker adrenal suppression), whole curve of DHEAS, 17-OHP, Δ4-ASD, TT and LH; [iii] significantly lower sex-hormone binding globulin (SHBG).&lt;/p&gt;&lt;p&gt;Even if most of the parameters evaluated were statistically similar in the two sets of comparisons, interesting differences were observed. Women with PCOS exhibit higher androgen levels at baseline, after adrenal suppression and at the buserelin test, further to a higher ovarian volume. Of note, the percentage of women with HOMA-IR≥2.5 and serum insulin levels were greater in PCOS group compared to EuHyperA women. Moreover, within women with PCOS, the HR subgroup has higher insulin levels compared to the NR subgroup,","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"37 ","pages":"Article 100368"},"PeriodicalIF":4.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000395/pdfft?md5=94cd4662b4e20d41249569ab386aed4e&pid=1-s2.0-S2214623724000395-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142164395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}